Clinical Trial Update: Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 clinical trial investigating GSK3326595 and other agents for myelodysplastic syndrome and acute myeloid leukemia has results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• GSK3326595

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-02-06